Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.30 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | PLAT | P00750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23833434 | 0.77 | CES1 (0.48) | ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL5784920 | 0.76 | ALDH1A1 (0.39) | ALDH1A1TDP1MEN1KMT2AKDM4E | |
| SCHEMBL25272109 | 0.76 | LOX (0.44) | ALDH1A1HSD17B10TDP1KDM4E | |
| SCHEMBL28722526 | 0.75 | KDM4E (0.40) | ALDH1A1HSD17B10TDP1MEN1KMT2A | |
| SCHEMBL9572453 | 0.74 | MEN1 (0.53) | ALDH1A1MEN1KMT2AKDM4EPLAU | |
| SCHEMBL25270609 | 0.73 | JAK2 (0.39) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL17593320 | 0.73 | KMT2A (0.38) | MEN1KMT2A | |
| SCHEMBL29110383 | 0.73 | MEN1 (0.38) | MEN1KMT2AKDM4E | |
| SCHEMBL16702844 | 0.73 | KDM4E (0.47) | ALDH1A1MEN1KMT2AKDM4EPLG | |
| SCHEMBL11223738 | 0.73 | PLAU (0.44) | ALDH1A1MEN1KMT2AKDM4EPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4121030-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | Amathus Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-109641873-B | N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease | 诺华股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021188907-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| CN-113423702-A | N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use in the treatment of disease | 诺华股份有限公司 | 2021-09-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, PPM1D | ALDH1A1 2592/4885HSD17B10 3166/4885TDP1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.